Literature DB >> 1710289

Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes.

M E Levely1, C A Bannow, C W Smith, J A Nicholas.   

Abstract

The lymphocyte proliferative responses to respiratory syncytial virus (RSV) were evaluated for 10 healthy adult donors and compared with proliferative responses to a chimeric glycoprotein (FG glycoprotein) which consists of the extracellular domains of both the F and G proteins of RSV and which is produced from a recombinant baculovirus. The lymphocytes of all 10 donors responded to RSV, and the proliferative responses to the whole virus were highly correlated with the responses to the FG glycoprotein. These data suggested that one or both of these glycoproteins of RSV were major target structures for stimulation of the human lymphocyte proliferative response among virus-specific memory T cells. The lymphocytes of four donors were evaluated further for their proliferative responses to a nested set of overlapping peptides modeled on the extracellular and cytoplasmic domains of the F protein of RSV. Strikingly, the lymphocytes of all 4 donors responded primarily to a region defined by a single peptide spanning residues 338 to 355, and the lymphocytes of 2 donors responded to an overlapping peptide spanning residues 328 to 342 also, thus defining a region of the F1 subunit within residues 328 to 355 that may circumscribe an immunodominant site for stimulation of human T cells from a variety of individuals. This region of the F protein is highly conserved among A and B subgroup viruses. As revealed by monoclonal antibody blocking studies, the lymphocytes responding to this antigenic site had characteristics consistent with T helper cells. Similar epitope mapping studies were performed with BALB/c mice immunized with the FG protein in which a relatively hydrophobic peptide spanning residues 51 to 65 within the F2 subunit appeared to be the major T cell recognition determinant. The data are discussed with respect to an antigenic map of the F protein and the potential construction of a synthetic vaccine for RSV.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710289      PMCID: PMC241409     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Immunization of cotton rats with the human respiratory syncytial virus F glycoprotein produced using a baculovirus vector.

Authors:  M W Wathen; R J Brideau; D R Thomsen
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

2.  Immunovirological studies on human respiratory syncytial virus structural proteins.

Authors:  M Trudel; F Nadon; C Séguin; S Ghoubril; P Payment; P Trépanier
Journal:  Can J Microbiol       Date:  1986-01       Impact factor: 2.419

3.  Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function.

Authors:  J A Beeler; K van Wyke Coelingh
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

4.  Helper T cell recognition of respiratory syncytial virus in mice.

Authors:  P J Openshaw; R M Pemberton; L A Ball; G W Wertz; B A Askonas
Journal:  J Gen Virol       Date:  1988-02       Impact factor: 3.891

5.  Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein.

Authors:  R J Brideau; R R Walters; M A Stier; M W Wathen
Journal:  J Gen Virol       Date:  1989-10       Impact factor: 3.891

6.  Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins.

Authors:  E E Walsh; C B Hall; J J Schlesinger; M W Brandriss; S Hildreth; P Paradiso
Journal:  J Gen Virol       Date:  1989-11       Impact factor: 3.891

7.  Characterization of a novel human respiratory syncytial virus chimeric FG glycoprotein expressed using a baculovirus vector.

Authors:  M W Wathen; R J Brideau; D R Thomsen; B R Murphy
Journal:  J Gen Virol       Date:  1989-10       Impact factor: 3.891

8.  Primary respiratory syncytial virus infection in mice.

Authors:  B S Graham; M D Perkins; P F Wright; D T Karzon
Journal:  J Med Virol       Date:  1988-10       Impact factor: 2.327

9.  Neutralization of respiratory syncytial virus by individual and mixtures of F and G protein monoclonal antibodies.

Authors:  L J Anderson; P Bingham; J C Hierholzer
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

10.  Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants.

Authors:  C R Bangham; P J Openshaw; L A Ball; A M King; G W Wertz; B A Askonas
Journal:  J Immunol       Date:  1986-12-15       Impact factor: 5.422

View more
  11 in total

1.  Identification of canine helper T-cell epitopes from the fusion protein of canine distemper virus.

Authors:  S Ghosh; J Walker; D C Jackson
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

2.  Structural and Nonstructural Viral Proteins Are Targets of T-Helper Immune Response against Human Respiratory Syncytial Virus.

Authors:  Elena Lorente; Alejandro Barriga; Eilon Barnea; Carmen Mir; John A Gebe; Arie Admon; Daniel López
Journal:  Mol Cell Proteomics       Date:  2016-04-18       Impact factor: 5.911

Review 3.  Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.

Authors:  Matthew R Olson; Steven M Varga
Journal:  Expert Rev Vaccines       Date:  2008-10       Impact factor: 5.217

4.  Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein.

Authors:  L de Waal; S Yüksel; A H Brandenburg; J P M Langedijk; K Sintnicolaas; G M G M Verjans; A D M E Osterhaus; R L de Swart
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

5.  Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation.

Authors:  Teresa R Johnson; David Rangel; Barney S Graham; Douglas E Brough; Jason G Gall
Journal:  Mol Ther       Date:  2013-06-10       Impact factor: 11.454

6.  Immunodominant T-cell epitopes of rubella virus structural proteins defined by synthetic peptides.

Authors:  M McCarthy; A Lovett; R H Kerman; A Overstreet; J S Wolinsky
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

7.  Identification of immunodominant epitopes derived from the respiratory syncytial virus fusion protein that are recognized by human CD4 T cells.

Authors:  Grada M van Bleek; Martien C Poelen; Robbert van der Most; Humphrey F Brugghe; Hans A M Timmermans; Claire J Boog; Peter Hoogerhout; Henny G Otten; Cécile A C M van Els
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

Review 8.  Nanoparticle vaccines against respiratory syncytial virus.

Authors:  Laura M Stephens; Steven M Varga
Journal:  Future Virol       Date:  2020-11-30       Impact factor: 1.831

9.  Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus.

Authors:  Young-In Kim; John P DeVincenzo; Bart G Jones; Rajeev Rudraraju; Lisa Harrison; Rachel Meyers; Jeff Cehelsky; Rene Alvarez; Julia L Hurwitz
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

Review 10.  Respiratory syncytial virus.

Authors:  O Ruuskanen; P L Ogra
Journal:  Curr Probl Pediatr       Date:  1993-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.